Document is current

Article History

Received: 24 May 2021

Accepted: 5 September 2021

First Online: 3 November 2021

Declarations

:

: The clinical trial called “SENTAD- COVID Study” was designed by <i>Abu Dhabi Stem Cells Center (ADSCC)</i>, according to the research project approved by the <i>ADSCC Research Ethics Committee</i> on April 4th, 2020, and later by a conditional exceptional approval letter by the <i>Ministry of Health and Prevention of the UAE</i>, via the <i>Emirates Institutional Review Board (IRB) for COVID-19 Research Committee</i>, on June, 25th 2020<b><i>.</i></b> The <i>Helsinki Declaration</i> was based on patients’ informed consent and the ethical conduction of all participants.

: The PB-NHESC-C treated patient No. 4 gave a written consent to publish his CT chest images.

: The procedure for obtaining the PB-NHESC-C mentioned in this report was advanced through research conducted and patented for ADSCC by YVC, AABH, and FMA. We declare that YMCA, CAVV, PS, YMA, AA, LAH, GMTZ, and RARJ are also staff members of ADSCC. For the rest thereof the co-authors, there are no competing interests. In May 2020, the patented procedure was approved by the Ministry of Economy of the United Arab Emirates, and also in May 2020, 5 of the authors (FMA, YVC, RARJ, AABH, and YMCA) received 3 Copyrights from the INTEROCO Copyright Office (EC-01-002809, EC-01-002810, and EC-01-002811), so this procedure including nebulization has been accredited to ADSCC. Nevertheless, YVC and the other patent authors resigned to be eligible to receive equity due to the licensing of this procedure.